HALO
HALOZYME THERAPEUTICS, INC.Company Information
- Company Name
- HALOZYME THERAPEUTICS, INC.
- CIK
- CIK0001159036
- Category
- Large accelerated filer
- Ticker: Exchange
- HALO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- HALO
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-16
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 223,469
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 118,345,291
- Shares outstanding
- 117,274,000
- Ownership
- 100.91%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 22.84%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 163 | 310 | 134 | 420 | 62 | 176 | 116 | 154 | 188 | 165 | 118 | 274 | ||||||
| Debt Securities Available For Sale Excluding Accrued Interest Current | 68 | 9 | 9 | 282 | 486 | 572 | 480 | 512 | 341 | 299 | 218 | 209 | ||||||
| Inventory Net | 137 | 155 | 176 | 186 | 182 | 165 | 142 | 131 | 159 | 169 | 128 | 129 | ||||||
| Prepaid Expense And Other Assets Current | 109 | 71 | 65 | 95 | 77 | 45 | 39 | 44 | 85 | 46 | 49 | 49 | ||||||
| Assets Current | 933 | 1,003 | 825 | 1,329 | 1,123 | 1,262 | 1,085 | 1,127 | 988 | 874 | 746 | 879 | ||||||
| Prepaid Expense And Other Assets Noncurrent | 55 | 51 | 54 | 56 | 56 | 56 | 81 | 80 | 52 | 17 | 18 | 18 | ||||||
| Goodwill | 582 | 582 | 580 | 417 | 417 | 417 | 417 | 417 | 417 | 417 | 417 | 417 | ||||||
| Intangible Assets Net Excluding Goodwill | 922 | 952 | 981 | 349 | 366 | 384 | 402 | 420 | 437 | 455 | 473 | 491 | ||||||
| Deferred Income Tax Assets Net | - | - | 0 | 0 | 20 | 5 | 4 | 0 | 0 | 1 | 4 | 13 | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | 1 | 2 | 3 | - | 0 | 0 | 0 | - | - | - | 0 | 0 | ||||||
| Assets | 2,577 | 2,673 | 2,525 | 2,221 | 2,054 | 2,197 | 2,063 | 2,118 | 1,969 | 1,842 | 1,733 | 1,893 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 24 | 14 | 21 | 15 | 19 | 20 | 10 | 12 | 15 | 13 | 12 | 19 | ||||||
| Accrued Liabilities Current | 112 | 140 | 156 | 111 | 116 | 130 | 129 | 96 | 118 | 118 | 101 | 95 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Long Term Debt Current | 209 | 209 | - | 711 | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities Current | 344 | 363 | 177 | 837 | 134 | 150 | 139 | 109 | 133 | 132 | 112 | 115 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 2 | ||||||
| Long Term Debt Noncurrent | 1,938 | 1,936 | 2,143 | 800 | 1,509 | 1,507 | 1,506 | 1,504 | 1,503 | 1,501 | 1,499 | 1,498 | ||||||
| Other Liabilities Noncurrent | 103 | 106 | 114 | 72 | 78 | 56 | 55 | 40 | 31 | 31 | 38 | 28 | ||||||
| Deferred Income Tax Liabilities Net | 49 | 48 | 43 | 8 | - | - | 0 | 12 | 14 | - | - | - | ||||||
| Liabilities | 2,434 | 2,453 | 2,477 | 1,717 | 1,721 | 1,714 | 1,700 | 1,665 | 1,680 | 1,664 | 1,649 | 1,643 | ||||||
Stockholders Equity | ||||||||||||||||||
| Business Combination Contingent Consideration Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 0 | 27 | 12 | 24 | 0 | 8 | 0 | 62 | 31 | 12 | 2 | 26 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -8 | -13 | -18 | -22 | -28 | -3 | 4 | -7 | -2 | -1 | -9 | 1 | ||||||
| Retained Earnings Accumulated Deficit | 151 | 205 | 55 | 502 | 361 | 478 | 360 | 398 | 261 | 167 | 91 | 222 | ||||||
| Stockholders Equity | 144 | 220 | 49 | 504 | 333 | 482 | 364 | 453 | 289 | 178 | 84 | 249 | ||||||
| Liabilities And Stockholders Equity | 2,577 | 2,673 | 2,525 | 2,221 | 2,054 | 2,197 | 2,063 | 2,118 | 1,969 | 1,842 | 1,733 | 1,893 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 114 | 119 | 118 | 118 | 118 | 123 | 123 | 127 | 127 | 127 | 127 | 132 | ||||||
| Shares Outstanding | 114 | 119 | 118 | 118 | 118 | 123 | 123 | 127 | 127 | 127 | 127 | 132 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialHALOZYME THERAPEUTICS, INC. (HALO) — SEC Financial Statements & Analysis
HALOZYME THERAPEUTICS, INC. (HALO) is a biological products, (no diagnostic substances) company, incorporated in DE. HALOZYME THERAPEUTICS, INC. trades on Nasdaq as: HALO. HALOZYME THERAPEUTICS, INC. (HALO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, HALOZYME THERAPEUTICS, INC. carries a market cap of $9.18B, a P/E ratio of 22.19x, a P/B ratio of 63.95x, a P/S ratio of 5.52x, an enterprise value of $11.16B, and an EV/EBITDA multiple of 18.24x. On profitability, it posts a gross margin of 82.42%, an operating margin of 35.90%, a net margin of 24.86%, a Return on Equity (ROE) of 173.67%, a Return on Assets (ROA) of 17.86%, and a Return on Invested Capital (ROIC) of 21.37%. Per share, it reports EPS of $3.53, diluted EPS of $3.41, free cash flow per share of $6.87, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 41.15% year-over-year, net income growth of -25.78% year-over-year, and EPS growth of -23.21% year-over-year. On the balance sheet, it maintains a current ratio of 2.71x, a quick ratio of 1.99x, working capital of $588.59M, a debt-to-equity ratio of 16.96x, a debt ratio of 0.94, an interest coverage ratio of 29.41x, free cash flow of $806.22M (TTM), and net debt of $1.98B. Figures sourced from SEC EDGAR.
- Market Cap
- $9.18B
- P/E TTM
- 22.19x
- EPS TTM
- $3.53
- P/B TTM
- 63.95x
- ROE TTM
- 173.67%
- ROA TTM
- 17.86%
- Debt To Equity
- 16.96x
- Free Cash Flow TTM
- $806.22M
- Net Revenue TTM Growth 1Y
- 41.15%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is HALOZYME THERAPEUTICS, INC. in?
HALOZYME THERAPEUTICS, INC. (HALO) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does HALO trade on?
HALOZYME THERAPEUTICS, INC. (HALO) trades on the Nasdaq.
Where is HALOZYME THERAPEUTICS, INC. incorporated?
HALOZYME THERAPEUTICS, INC. is incorporated in DE.
When was HALOZYME THERAPEUTICS, INC. (HALO)'s most recent SEC filing?
HALOZYME THERAPEUTICS, INC. (HALO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is HALO's market cap?
HALOZYME THERAPEUTICS, INC. (HALO) has a market capitalization of $9.18B as of 2026-06-30.
What is HALO's P/E ratio?
HALOZYME THERAPEUTICS, INC. (HALO)'s trailing twelve month P/E ratio is 22.19x as of 2026-06-30.
What is HALO's EPS (earnings per share)?
HALOZYME THERAPEUTICS, INC. (HALO)'s trailing twelve month EPS is $3.53 as of 2026-06-30.
What is HALO's ROE (return on equity)?
HALOZYME THERAPEUTICS, INC. (HALO)'s trailing twelve month Return on Equity (ROE) is 173.67% as of 2026-06-30.
What is HALO's ROA (return on assets)?
HALOZYME THERAPEUTICS, INC. (HALO)'s trailing twelve month Return on Assets (ROA) is 17.86% as of 2026-06-30.
What is HALO's ROIC (return on invested capital)?
HALOZYME THERAPEUTICS, INC. (HALO)'s trailing twelve month Return on Invested Capital (ROIC) is 21.37% as of 2026-06-30.
What is HALO's EV/EBITDA?
HALOZYME THERAPEUTICS, INC. (HALO)'s trailing twelve month EV/EBITDA is 18.24x as of 2026-06-30.